Loading…
Progressive Osseous Heteroplasia
Progressive osseous heteroplasia (POH) is a recently described genetic disorder of mesenchymal differentiation characterized by dermal ossification during infancy and progressive heterotopic ossification of cutaneous, subcutaneous, and deep connective tissues during childhood. The disorder can be di...
Saved in:
Published in: | Journal of bone and mineral research 2000-11, Vol.15 (11), p.2084-2094 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4643-3dcc55c1e02f97653c3ee1d6280aeb4a188abc31fa37499e95d85be68fa7c8173 |
---|---|
cites | cdi_FETCH-LOGICAL-c4643-3dcc55c1e02f97653c3ee1d6280aeb4a188abc31fa37499e95d85be68fa7c8173 |
container_end_page | 2094 |
container_issue | 11 |
container_start_page | 2084 |
container_title | Journal of bone and mineral research |
container_volume | 15 |
creator | Kaplan, Frederick S. Shore, Eileen M. |
description | Progressive osseous heteroplasia (POH) is a recently described genetic disorder of mesenchymal differentiation characterized by dermal ossification during infancy and progressive heterotopic ossification of cutaneous, subcutaneous, and deep connective tissues during childhood. The disorder can be distinguished from fibrodysplasia ossificans progressiva (FOP) by the presence of cutaneous ossification, the absence of congenital malformations of the skeleton, the absence of inflammatory tumorlike swellings, the asymmetric mosaic distribution of lesions, the absence of predictable regional patterns of heterotopic ossification, and the predominance of intramembranous rather than endochondral ossification. POH can be distinguished from Albright hereditary osteodystrophy (AHO) by the progression of heterotopic ossification from skin and subcutaneous tissue into skeletal muscle, the presence of normal endocrine function, and the absence of a distinctive habitus associated with AHO. Although the genetic basis of POH is unknown, inactivating mutations of the GNAS1 gene are associated with AHO. The report in this issue of the JBMR of 2 patients with combined features of POH and AHO—one with classic AHO, severe POH‐like features, and reduced levels of Gsα protein and one with mild AHO, severe POH‐like features, reduced levels of Gsα protein, and a mutation in GNAS1—suggests that classic POH also could be caused by GNAS1 mutations. This possibility is further supported by the identification of a patient with atypical but severe platelike osteoma cutis (POC) and a mutation in GNAS1, indicating that inactivating mutations in GNAS1 may lead to severe progressive heterotopic ossification of skeletal muscle and deep connective tissue independently of AHO characteristics. These observations suggest that POH may lie at one end of a clinical spectrum of ossification disorders mediated by abnormalities in GNAS1 expression and impaired activation of adenylyl cyclase. Analysis of patients with classic POH (with no AHO features) is necessary to determine whether the molecular basis of POH is caused by inactivating mutations in the GNAS1 gene. |
doi_str_mv | 10.1359/jbmr.2000.15.11.2084 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72429252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17717730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4643-3dcc55c1e02f97653c3ee1d6280aeb4a188abc31fa37499e95d85be68fa7c8173</originalsourceid><addsrcrecordid>eNqNkE1LAzEQhoMotlb_gUgP4m1rZvOxyU0tapVKRfQcstlZ2bLbrUmr9N-bpYUeFQKTwDPvZB5CzoGOgAl9Pc8bP0opjU8xAohXxQ9IH0TKEi4VHJI-VYonlDPokZMQ5pGVQspj0gOgOmUa-mT46ttPjyFU3zichYDtOgwnuELfLmsbKntKjkpbBzzb1QH5eLh_H0-S6ezxaXw7TRyXnCWscE4IB0jTUmdSMMcQoZCpohZzbkEpmzsGpWUZ1xq1KJTIUarSZk5Bxgbkapu79O3XGsPKNFVwWNd20f3JZClPdRqX-wuELIuH0QjyLeh8G4LH0ix91Vi_MUBNp9B0Ck2n0IAwAKZTGNsudvnrvMFi37RzFoHLHWCDs3Xp7cJVYc8JRjPe5dxssZ-qxs2_Zpvnu5c3IQUFEacx9gtoKYu9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17717730</pqid></control><display><type>article</type><title>Progressive Osseous Heteroplasia</title><source>Oxford Journals Online</source><creator>Kaplan, Frederick S. ; Shore, Eileen M.</creator><creatorcontrib>Kaplan, Frederick S. ; Shore, Eileen M.</creatorcontrib><description>Progressive osseous heteroplasia (POH) is a recently described genetic disorder of mesenchymal differentiation characterized by dermal ossification during infancy and progressive heterotopic ossification of cutaneous, subcutaneous, and deep connective tissues during childhood. The disorder can be distinguished from fibrodysplasia ossificans progressiva (FOP) by the presence of cutaneous ossification, the absence of congenital malformations of the skeleton, the absence of inflammatory tumorlike swellings, the asymmetric mosaic distribution of lesions, the absence of predictable regional patterns of heterotopic ossification, and the predominance of intramembranous rather than endochondral ossification. POH can be distinguished from Albright hereditary osteodystrophy (AHO) by the progression of heterotopic ossification from skin and subcutaneous tissue into skeletal muscle, the presence of normal endocrine function, and the absence of a distinctive habitus associated with AHO. Although the genetic basis of POH is unknown, inactivating mutations of the GNAS1 gene are associated with AHO. The report in this issue of the JBMR of 2 patients with combined features of POH and AHO—one with classic AHO, severe POH‐like features, and reduced levels of Gsα protein and one with mild AHO, severe POH‐like features, reduced levels of Gsα protein, and a mutation in GNAS1—suggests that classic POH also could be caused by GNAS1 mutations. This possibility is further supported by the identification of a patient with atypical but severe platelike osteoma cutis (POC) and a mutation in GNAS1, indicating that inactivating mutations in GNAS1 may lead to severe progressive heterotopic ossification of skeletal muscle and deep connective tissue independently of AHO characteristics. These observations suggest that POH may lie at one end of a clinical spectrum of ossification disorders mediated by abnormalities in GNAS1 expression and impaired activation of adenylyl cyclase. Analysis of patients with classic POH (with no AHO features) is necessary to determine whether the molecular basis of POH is caused by inactivating mutations in the GNAS1 gene.</description><identifier>ISSN: 0884-0431</identifier><identifier>EISSN: 1523-4681</identifier><identifier>DOI: 10.1359/jbmr.2000.15.11.2084</identifier><identifier>PMID: 11092391</identifier><identifier>CODEN: JBMREJ</identifier><language>eng</language><publisher>Washington, DC: John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</publisher><subject>Albright hereditary osteodystrophy ; Biological and medical sciences ; Diseases of the osteoarticular system ; fibrodysplasia ossificans progressiva ; Fibrous Dysplasia, Polyostotic - etiology ; GNAS1 ; GTP-Binding Protein alpha Subunits, Gs - genetics ; heterotopic ossification ; Humans ; Malformations and congenital and or hereditary diseases involving bones. Joint deformations ; Medical sciences ; Ossification, Heterotopic - etiology ; Ossification, Heterotopic - pathology ; Ossification, Heterotopic - therapy ; Prognosis ; progressive osseous heteroplasia ; Self-Help Groups ; Skin Diseases - etiology ; Skin Diseases - pathology</subject><ispartof>Journal of bone and mineral research, 2000-11, Vol.15 (11), p.2084-2094</ispartof><rights>Copyright © 2000 ASBMR</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4643-3dcc55c1e02f97653c3ee1d6280aeb4a188abc31fa37499e95d85be68fa7c8173</citedby><cites>FETCH-LOGICAL-c4643-3dcc55c1e02f97653c3ee1d6280aeb4a188abc31fa37499e95d85be68fa7c8173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1530744$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11092391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaplan, Frederick S.</creatorcontrib><creatorcontrib>Shore, Eileen M.</creatorcontrib><title>Progressive Osseous Heteroplasia</title><title>Journal of bone and mineral research</title><addtitle>J Bone Miner Res</addtitle><description>Progressive osseous heteroplasia (POH) is a recently described genetic disorder of mesenchymal differentiation characterized by dermal ossification during infancy and progressive heterotopic ossification of cutaneous, subcutaneous, and deep connective tissues during childhood. The disorder can be distinguished from fibrodysplasia ossificans progressiva (FOP) by the presence of cutaneous ossification, the absence of congenital malformations of the skeleton, the absence of inflammatory tumorlike swellings, the asymmetric mosaic distribution of lesions, the absence of predictable regional patterns of heterotopic ossification, and the predominance of intramembranous rather than endochondral ossification. POH can be distinguished from Albright hereditary osteodystrophy (AHO) by the progression of heterotopic ossification from skin and subcutaneous tissue into skeletal muscle, the presence of normal endocrine function, and the absence of a distinctive habitus associated with AHO. Although the genetic basis of POH is unknown, inactivating mutations of the GNAS1 gene are associated with AHO. The report in this issue of the JBMR of 2 patients with combined features of POH and AHO—one with classic AHO, severe POH‐like features, and reduced levels of Gsα protein and one with mild AHO, severe POH‐like features, reduced levels of Gsα protein, and a mutation in GNAS1—suggests that classic POH also could be caused by GNAS1 mutations. This possibility is further supported by the identification of a patient with atypical but severe platelike osteoma cutis (POC) and a mutation in GNAS1, indicating that inactivating mutations in GNAS1 may lead to severe progressive heterotopic ossification of skeletal muscle and deep connective tissue independently of AHO characteristics. These observations suggest that POH may lie at one end of a clinical spectrum of ossification disorders mediated by abnormalities in GNAS1 expression and impaired activation of adenylyl cyclase. Analysis of patients with classic POH (with no AHO features) is necessary to determine whether the molecular basis of POH is caused by inactivating mutations in the GNAS1 gene.</description><subject>Albright hereditary osteodystrophy</subject><subject>Biological and medical sciences</subject><subject>Diseases of the osteoarticular system</subject><subject>fibrodysplasia ossificans progressiva</subject><subject>Fibrous Dysplasia, Polyostotic - etiology</subject><subject>GNAS1</subject><subject>GTP-Binding Protein alpha Subunits, Gs - genetics</subject><subject>heterotopic ossification</subject><subject>Humans</subject><subject>Malformations and congenital and or hereditary diseases involving bones. Joint deformations</subject><subject>Medical sciences</subject><subject>Ossification, Heterotopic - etiology</subject><subject>Ossification, Heterotopic - pathology</subject><subject>Ossification, Heterotopic - therapy</subject><subject>Prognosis</subject><subject>progressive osseous heteroplasia</subject><subject>Self-Help Groups</subject><subject>Skin Diseases - etiology</subject><subject>Skin Diseases - pathology</subject><issn>0884-0431</issn><issn>1523-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqNkE1LAzEQhoMotlb_gUgP4m1rZvOxyU0tapVKRfQcstlZ2bLbrUmr9N-bpYUeFQKTwDPvZB5CzoGOgAl9Pc8bP0opjU8xAohXxQ9IH0TKEi4VHJI-VYonlDPokZMQ5pGVQspj0gOgOmUa-mT46ttPjyFU3zichYDtOgwnuELfLmsbKntKjkpbBzzb1QH5eLh_H0-S6ezxaXw7TRyXnCWscE4IB0jTUmdSMMcQoZCpohZzbkEpmzsGpWUZ1xq1KJTIUarSZk5Bxgbkapu79O3XGsPKNFVwWNd20f3JZClPdRqX-wuELIuH0QjyLeh8G4LH0ix91Vi_MUBNp9B0Ck2n0IAwAKZTGNsudvnrvMFi37RzFoHLHWCDs3Xp7cJVYc8JRjPe5dxssZ-qxs2_Zpvnu5c3IQUFEacx9gtoKYu9</recordid><startdate>200011</startdate><enddate>200011</enddate><creator>Kaplan, Frederick S.</creator><creator>Shore, Eileen M.</creator><general>John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</general><general>American Society for Bone and Mineral Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>200011</creationdate><title>Progressive Osseous Heteroplasia</title><author>Kaplan, Frederick S. ; Shore, Eileen M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4643-3dcc55c1e02f97653c3ee1d6280aeb4a188abc31fa37499e95d85be68fa7c8173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Albright hereditary osteodystrophy</topic><topic>Biological and medical sciences</topic><topic>Diseases of the osteoarticular system</topic><topic>fibrodysplasia ossificans progressiva</topic><topic>Fibrous Dysplasia, Polyostotic - etiology</topic><topic>GNAS1</topic><topic>GTP-Binding Protein alpha Subunits, Gs - genetics</topic><topic>heterotopic ossification</topic><topic>Humans</topic><topic>Malformations and congenital and or hereditary diseases involving bones. Joint deformations</topic><topic>Medical sciences</topic><topic>Ossification, Heterotopic - etiology</topic><topic>Ossification, Heterotopic - pathology</topic><topic>Ossification, Heterotopic - therapy</topic><topic>Prognosis</topic><topic>progressive osseous heteroplasia</topic><topic>Self-Help Groups</topic><topic>Skin Diseases - etiology</topic><topic>Skin Diseases - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaplan, Frederick S.</creatorcontrib><creatorcontrib>Shore, Eileen M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of bone and mineral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaplan, Frederick S.</au><au>Shore, Eileen M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progressive Osseous Heteroplasia</atitle><jtitle>Journal of bone and mineral research</jtitle><addtitle>J Bone Miner Res</addtitle><date>2000-11</date><risdate>2000</risdate><volume>15</volume><issue>11</issue><spage>2084</spage><epage>2094</epage><pages>2084-2094</pages><issn>0884-0431</issn><eissn>1523-4681</eissn><coden>JBMREJ</coden><abstract>Progressive osseous heteroplasia (POH) is a recently described genetic disorder of mesenchymal differentiation characterized by dermal ossification during infancy and progressive heterotopic ossification of cutaneous, subcutaneous, and deep connective tissues during childhood. The disorder can be distinguished from fibrodysplasia ossificans progressiva (FOP) by the presence of cutaneous ossification, the absence of congenital malformations of the skeleton, the absence of inflammatory tumorlike swellings, the asymmetric mosaic distribution of lesions, the absence of predictable regional patterns of heterotopic ossification, and the predominance of intramembranous rather than endochondral ossification. POH can be distinguished from Albright hereditary osteodystrophy (AHO) by the progression of heterotopic ossification from skin and subcutaneous tissue into skeletal muscle, the presence of normal endocrine function, and the absence of a distinctive habitus associated with AHO. Although the genetic basis of POH is unknown, inactivating mutations of the GNAS1 gene are associated with AHO. The report in this issue of the JBMR of 2 patients with combined features of POH and AHO—one with classic AHO, severe POH‐like features, and reduced levels of Gsα protein and one with mild AHO, severe POH‐like features, reduced levels of Gsα protein, and a mutation in GNAS1—suggests that classic POH also could be caused by GNAS1 mutations. This possibility is further supported by the identification of a patient with atypical but severe platelike osteoma cutis (POC) and a mutation in GNAS1, indicating that inactivating mutations in GNAS1 may lead to severe progressive heterotopic ossification of skeletal muscle and deep connective tissue independently of AHO characteristics. These observations suggest that POH may lie at one end of a clinical spectrum of ossification disorders mediated by abnormalities in GNAS1 expression and impaired activation of adenylyl cyclase. Analysis of patients with classic POH (with no AHO features) is necessary to determine whether the molecular basis of POH is caused by inactivating mutations in the GNAS1 gene.</abstract><cop>Washington, DC</cop><pub>John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</pub><pmid>11092391</pmid><doi>10.1359/jbmr.2000.15.11.2084</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0884-0431 |
ispartof | Journal of bone and mineral research, 2000-11, Vol.15 (11), p.2084-2094 |
issn | 0884-0431 1523-4681 |
language | eng |
recordid | cdi_proquest_miscellaneous_72429252 |
source | Oxford Journals Online |
subjects | Albright hereditary osteodystrophy Biological and medical sciences Diseases of the osteoarticular system fibrodysplasia ossificans progressiva Fibrous Dysplasia, Polyostotic - etiology GNAS1 GTP-Binding Protein alpha Subunits, Gs - genetics heterotopic ossification Humans Malformations and congenital and or hereditary diseases involving bones. Joint deformations Medical sciences Ossification, Heterotopic - etiology Ossification, Heterotopic - pathology Ossification, Heterotopic - therapy Prognosis progressive osseous heteroplasia Self-Help Groups Skin Diseases - etiology Skin Diseases - pathology |
title | Progressive Osseous Heteroplasia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A52%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progressive%20Osseous%20Heteroplasia&rft.jtitle=Journal%20of%20bone%20and%20mineral%20research&rft.au=Kaplan,%20Frederick%20S.&rft.date=2000-11&rft.volume=15&rft.issue=11&rft.spage=2084&rft.epage=2094&rft.pages=2084-2094&rft.issn=0884-0431&rft.eissn=1523-4681&rft.coden=JBMREJ&rft_id=info:doi/10.1359/jbmr.2000.15.11.2084&rft_dat=%3Cproquest_cross%3E17717730%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4643-3dcc55c1e02f97653c3ee1d6280aeb4a188abc31fa37499e95d85be68fa7c8173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17717730&rft_id=info:pmid/11092391&rfr_iscdi=true |